Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: 201107229 Principal Investigator: Vij, Ravi
Title: A Phase 1b, Open-label, Multicenter Study of BMS-936564 in Combination with Lenalidomide (Revlimid®) plus low-dose Dexamethasone, or with Bortezomib (Velcade®) plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma
Phase: I Disease Site: Multiple Myeloma
Participating Site(s):
 
Main Campus
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu

Description:
The purpose of this study is to determine 1) the safety and tolerability of multiple intravenous doses of BMS-936564 alone and as a combination therapy, and 2) the maximum tolerated dose of BMS-936564 in combination with Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in subjects with relapsed or refractory multiple myeloma.
 
More Information:
ClinicalTrials.gov Link
Internal Protocol Documents (requires Siteman administrative database password)